Abingworth’s CRISPR Therapeutics CRSP Stock Holding History

Abingworth’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-259,599	Closed	-$21.7M	–	16
2020 Q3	$21.7M	Sell	259,599 -259,599	-50%	-$23M	4.64%	5
2020 Q2	$38.1M	Hold	519,198	–	–	10.64%	4
2020 Q1	$22M	Hold	519,198	–	–	14.58%	3
2019 Q4	$31.6M	Sell	519,198 -109,200	-17%	-$5.96M	15.28%	3
2019 Q3	$25.7M	Sell	628,398 -542,870	-46%	-$25.9M	16.28%	2
2019 Q2	$55M	Hold	1,171,268	–	–	21.11%	2
2019 Q1	$41.8M	Hold	1,171,268	–	–	37.43%	1
2018 Q4	$33.5M	Sell	1,171,268 -65,934	-5%	-$2.29M	30.41%	1
2018 Q3	$54.9M	Hold	1,237,202	–	–	32.61%	1
2018 Q2	$72.7M	Sell	1,237,202 -650,000	-34%	-$37M	41.53%	1
2018 Q1	$86.2M	Sell	1,887,202 -64,157	-3%	-$2.65M	53.59%	1
2017 Q4	$45.8M	Sell	1,951,359 -20,548	-1%	-$390K	33.18%	1
2017 Q3	$35.1M	Sell	1,971,907 -472,902	-19%	-$8.57M	24.33%	1
2017 Q2	$39M	Sell	2,444,809 -157,005	-6%	-$2.59M	31.01%	1
2017 Q1	$56.6M	Hold	2,601,814	–	–	42.2%	1
2016 Q4	$52M	Buy	+2,601,814	New	+$48.6M	43.5%	1

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Abingworth's CRSP Position: Q4 2020 in Review

Abingworth sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 259,599 shares — an estimated $21.7M sold.

Abingworth first reported a position in CRSP in Q4 2016 and held it in 16 quarters. The position peaked at $86.2M in Q1 2018. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

Abingworth reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
Abingworth sold 259,599 CRISPR Therapeutics shares in Q4 2020, an estimated $21.7M.
Abingworth first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 16 quarters.
Abingworth's CRISPR Therapeutics position peaked at $86.2M in Q1 2018.
412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Abingworth's 13F filing for Q4 2020, filed 1 Mar 2021.